The webinar will be presented by AdAlta’s Chief Executive Officer & Managing Director, Dr Tim Oldham, and will be followed by a short Q&A session
In his webinar presentation, Dr Oldham will discuss the results of AdAlta’s strategic review and portfolio prioritization announced separately today, including:
• What drives AdAlta’s “East to West” cellular immunotherapy strategy
• How the “East to West” strategy will be AdAlta’s key driver of future pipeline growth and value creation
• Recent progress made in executing the “East to West” strategy, including the signing of term sheets
• How the value inherent in AdAlta’s fibrosis disease drug candidate AD-214 will be monetised.
AdAlta Investor Webinar Registration Details:
DATE: Tuesday 11 February 2025
TIME: 12.00 noon AEDT
FORMAT: Zoom
Please register in advance using the following link:
https://us02web.zoom.us/webinar/register/WN_RNWwB4MRRaeLxrjeb7ujOw
After registering, you will receive a confirmation email containing information about joining the webinar.
Reference Documents:
• ASX announcement: “East to West” cellular immunotherapy strategy prioritized
https://investorhub.adalta.com.au/link/vPnple
To read the investor presentation, click here
About us:
About AdAlta
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today’s most challenging medical conditions.
The i-body® technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.
AdAlta’s lead i-body® enabled candidate is AD-214. At any time, 500,000 patients with lung fibrosis (IPF) face death from inability to breath, despite spending US$4.3 billion per year on pharmaceutical therapies. Fibrosis can affect all organ systems and around 45% of all western country deaths have a fibrotic disease component. AD-214 is taking a wholly new approach to treat IPF and other fibrotic diseases. AD-214 is a first in class (first to utilize this mode of action) molecule and has been shown to be safe in Phase I clinical studies and effective in multiple animal and laboratory models of fibrotic disease. In accord with its business model, AdAlta is creating a private, unlisted subsidiary called AdSolis to advance AD-214 into Phase II clinical trials through licensing and/or third party investment.
AdAlta believes that the i-body® technology is ideally suited for use in the creation of advanced cellular immunotherapies for cancer and that this field represents an opportunity to expand its clinical stage pipeline.It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta’s i-body® technology. It has appointed Cell Therapies Pty Ltd, Australia’s leading manufacturer of cell and gene therapies, as AdCella’s preferred manufacturer.
The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body® platform by discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.
To learn more please visit: www.adalta.com.au
Contact details:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
+61 3 9479 5159
[email protected]
Media & Investor Enquiries
The Capital Network
Julia Maguire
+61 2 7257 7338
[email protected]